{"annotatable":{"parts":["s1v1","s2v1","s3v1","s4v1","s5v1","s6v1","s7v1","s8v1","s9v1","s10v1","s11v1","s12v1","s13v1","s14v1","s15v1","s16v1","s17v1","s18v1"]},"anncomplete":true,"sources":[],"metas":{"m_82":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_83":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_84":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_85":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_35":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_86":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}}},"entities":[{"classId":"e_109","part":"s1v1","offsets":[{"start":15,"text":"Randomized Controlled Trial"}],"coordinates":[{"x":"197.34","y":"130.07"},{"x":"387.92","y":"140.04"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_109","part":"s1v1","offsets":[{"start":1429,"text":"A total of 525 patients with documented cardiovascular disease, type 2diabetes, hypercholesterolemia, or hypertension and levels of LDL-cholesterol, blood pressure orHbA1c that exceeded goals established by national guidelines were randomized to NP/CHW(n=261) or EUC (n=264) groups"}],"coordinates":[{"x":"218.57","y":"450.35"},{"x":"238.15","y":"492.92"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_109","part":"s1v1","offsets":[{"start":1661,"text":"randomized to NP/CHW(n=261) or EUC (n=264) groups"}],"coordinates":[{"x":"379.89","y":"474.35"},{"x":"238.15","y":"492.92"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_128","part":"s3v1","offsets":[{"start":1552,"text":"COACH was a randomized controlled trial in which 525 patients were randomly assigned toone of two groups: comprehensive intensive management of cardiovascular disease (CVD)risk factors by a NP/CHW team or an enhanced usual care (EUC) control group."}],"coordinates":[{"x":"150.00","y":"348.27"},{"x":"471.59","y":"378.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_123","part":"s3v1","offsets":[{"start":1552,"text":"COACH was a randomized controlled trial in which 525 patients were randomly assigned toone of two groups: comprehensive intensive management of cardiovascular disease (CVD)risk factors by a NP/CHW team or an enhanced usual care (EUC) control group."}],"coordinates":[{"x":"150.00","y":"348.27"},{"x":"471.59","y":"378.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_123","part":"s3v1","offsets":[{"start":1552,"text":"COACH was a randomized controlled trial in which 525 patients were randomly assigned toone of two groups: comprehensive intensive management of cardiovascular disease (CVD)risk factors by a NP/CHW team or an enhanced usual care (EUC) control group"}],"coordinates":[{"x":"150.00","y":"348.27"},{"x":"469.09","y":"378.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_136","part":"s3v1","offsets":[{"start":1801,"text":"Individualsin the control group received usual care from their primary provider which was enhanced byfeedback regarding CVD risk factors provided to the patient and their provider. Those in theintensive intervention group received enhanced usual care plus management by the NP/CHW team. The program included aggressive pharmacologic management, tailorededucational and behavioral counseling for lifestyle modification, identification of barriers toadherence and control, phone follow-ups between visits and pre-appointment reminders."}],"coordinates":[{"x":"474.09","y":"372.27"},{"x":"503.54","y":"450.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_176","part":"s5v1","offsets":[{"start":2451,"text":"The primary outcomes were changes from baseline to one year in lipids, BP, HbA1c andpatients’ perceptions of the quality of their chronic illness care."}],"coordinates":[{"x":"150.00","y":"490.27"},{"x":"402.73","y":"508.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_201","part":"s5v1","offsets":[{"start":2451,"text":"The primary outcomes were changes from baseline to one year in lipids, BP, HbA1c andpatients’ perceptions of the quality of their chronic illness care. The primary outcomes alsowere operationalized as meeting the goals for secondary prevention or experiencing aclinically significant change as follows: HbA1c < 7% or clinically significant decrease of ≥0.5%; systolic BP < 140 mm Hg or < 130 mm Hg if patient had diabetes or kidney diseaseor clinically significant decrease of ≥ 10 mm Hg; and LDL cholesterol level, < 100 mg/dLor < 130 if no CVD or diabetes or a clinically significant decrease of ≥ 20%. The chemistrylaboratory at Johns Hopkins performed all biochemical measures. Total cholesterol,triglycerides, and high-density lipoprotein cholesterol (HDL-C) were measured directly aftera 12 hour fast. Low-density lipoprotein cholesterol (LDL-C) was estimated using theFriedewald equation.31 In the event of triglyceride levels greater than 400 mg/dL, directmeasurement of LDL-C through ultracentrifugation methods was performed. In participantswith diabetes, HbA1c was measured using high pressure liquid chromatography. Bloodpressure was measured using the Omron Digital Blood Pressure Monitor HEM-907XLautomatic blood pressure device according to JNC VII guidelines, following five minutes ofquiet rest, in the right arm with the person seated in a chair with arm supported at heartlevel. The average of three blood pressures was recorded."}],"coordinates":[{"x":"150.00","y":"490.27"},{"x":"379.92","y":"688.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_189","part":"s5v1","offsets":[{"start":2451,"text":"The primary outcomes were changes from baseline to one year in lipids, BP, HbA1c andpatients’ perceptions of the quality of their chronic illness care. The primary outcomes alsowere operationalized as meeting the goals for secondary prevention or experiencing aclinically significant change as follows: HbA1c < 7% or clinically significant decrease of ≥0.5%; systolic BP < 140 mm Hg or < 130 mm Hg if patient had diabetes or kidney diseaseor clinically significant decrease of ≥ 10 mm Hg; and LDL cholesterol level, < 100 mg/dLor < 130 if no CVD or diabetes or a clinically significant decrease of ≥ 20%. The chemistrylaboratory at Johns Hopkins performed all biochemical measures. Total cholesterol,triglycerides, and high-density lipoprotein cholesterol (HDL-C) were measured directly aftera 12 hour fast. Low-density lipoprotein cholesterol (LDL-C) was estimated using theFriedewald equation.31 In the event of triglyceride levels greater than 400 mg/dL, directmeasurement of LDL-C through ultracentrifugation methods was performed. In participantswith diabetes, HbA1c was measured using high pressure liquid chromatography. Bloodpressure was measured using the Omron Digital Blood Pressure Monitor HEM-907XLautomatic blood pressure device according to JNC VII guidelines, following five minutes ofquiet rest, in the right arm with the person seated in a chair with arm supported at heartlevel. The average of three blood pressures was recorded"}],"coordinates":[{"x":"150.00","y":"490.27"},{"x":"377.42","y":"688.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_209","part":"s5v1","offsets":[{"start":2451,"text":"The primary outcomes were changes from baseline to one year in lipids, BP, HbA1c andpatients’ perceptions of the quality of their chronic illness care."}],"coordinates":[{"x":"150.00","y":"490.27"},{"x":"402.73","y":"508.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_209","part":"s6v1","offsets":[{"start":1901,"text":"The primary outcomes are changes from baseline to one year in lipids, BP, HgA1c, and thepatient’s perception of chronic illness care. Analysis followed the intention- to- treat modelincluding all randomized participants in the analyses according to their original assignment.Participants who withdrew or did not complete the one year assessment were included in theanalysis. Missing data were imputed with multiple imputation. Multiple imputation is anadvanced statistical method for handling missing data.38 This computationally intensiveapproach uses multiple linear regression to predict missing values with observed data. Theprocedure is repeated with five iterations. Repeatedly imputing missing values allows forquantifying the uncertainty resulting from sampling error."}],"coordinates":[{"x":"150.00","y":"396.27"},{"x":"381.36","y":"498.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_148","part":"s6v1","offsets":[{"start":2035,"text":"Analysis followed the intention- to- treat modelincluding all randomized participants in the analyses according to their original assignment."}],"coordinates":[{"x":"324.68","y":"408.27"},{"x":"517.18","y":"426.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_214","part":"s6v1","offsets":[{"start":2176,"text":"Participants who withdrew or did not complete the one year assessment were included in theanalysis. Missing data were imputed with multiple imputation."}],"coordinates":[{"x":"150.00","y":"432.27"},{"x":"400.28","y":"450.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_160","part":"s7v1","offsets":[{"start":280,"text":"A total of 84 percent of patients randomized to the intervention group completed an initialvisit, and 70 percent had at least four in-person visits with the nurse. Patients in theintervention group had a mean of 7 ± 3 in-person visits and 6 ± 5 telephone visits with theNP/CHW team."}],"coordinates":[{"x":"150.00","y":"120.27"},{"x":"213.33","y":"162.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_165","part":"s7v1","offsets":[{"start":636,"text":"At 12 months, patients in the intervention group had significantly greater overallimprovement in total cholesterol, LDL cholesterol, triglycerides, systolic and diastolic BP,HbA1c, and perceptions of the quality of their chronic illness care compared to patientsreceiving EUC (Table 2). The analyses using general linear mixed models controlled forage, sex, education, race, body mass index, insurance status, and an indicator of controlstatus at baseline. The estimated between group differences were clinically significant. Atthe 12 month follow-up, a significantly higher percentage of patients in the interventiongroup compared to the EUC group had values that reached guideline goals or showedclinically significant improvements in LDL cholesterol (EUC=58%; I=75%, p<0.001),systolic BP (EUC=74%; I=82%, p=0.018), and HbA1c (EUC=47%; I=60%, p=0.016)."}],"coordinates":[{"x":"150.00","y":"178.27"},{"x":"496.31","y":"292.84"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_121","part":"s14v1","offsets":[{"start":101,"text":"Baseline sample characteristicsCharacteristic Intervention (n = 261) Usual Care (n = 264) PAge, y, mean (SD)* 54.3 (12.0) 54.7 (11.5) 0.692Female, n (%) 187 (71.7) 187 (70.8) 0.837Marital status, n (%) 0.591  Single 61 (23.4) 69 (26.1)  Married 86 (33.0) 80 (30.3)  Separated 19 (7.3) 28 (10.6)  Widowed 39 (14.9) 37 (14.0)  Divorced 56 (21.5) 50 (18.9)Race, n (%) 0.946  Non-black 54 (20.7) 54 (20.5)  Black 207 (79.3) 210 (79.6)Education, n (%) 0.051  <High School 76 (29.1) 94 (35.6)  High school/GED 118 (45.2) 92 (34.9)  Some college 67 (25.7) 78 (29.6)Employment status, n (%) 0.318  Employed 110 (42.2) 100 (37.9)  Not employed 151 (57.9) 164 (62.1)Type of insurance, n (%) 0.403  Private 112 (42.9) 105 (39.8)  Medicare and/or Medicaid 106 (40.6) 101 (38.3)  Uninsured 43 (16.5) 55 (20.8)  Unknown 0 (0) 3 (1.1)Annual income, n (%) 0.223  <$20,000 137 (52.5) 149 (56.4)  ≥$20,000 120 (46.0) 105 (39.8)  Unknown 4 (1.5) 10 (3.8)Comorbidity score, mean (SD) 1.6 (1.3) 1.8)1.4) 0.193Diastolic Blood Pressure, mean (SD) 83.1 (12.6) 82.3 (13.0) 0.442Systolic Blood Pressure, mean (SD) 139.7 (23.8) 138.7 (19.9) 0.587Total Cholesterol, mean (SD) 199.7 (46.0) 191.3 (45.0) 0.036LDL-C†, mean (SD) 121.6 (40.0) 116.3 (40.5) 0.132HDL-C‡, mean (SD) 50.8 (14.7) 50.9 (13.6) 0.92Triglycerides, median (IQR)§ 113 (85) 105 (76) 0.220Hemoglobin A1c, mean (SD) 8.9 (2.2) 8.3 (1.9) 0.006PACIC||, mean (SD) 1.5 (0.9) 1.6 (0.9) 0.883"}],"coordinates":[{"x":"78.00","y":"98.27"},{"x":"377.57","y":"641.63"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}}],"relations":[]}